Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoyao Jieyu is a Traditional Chinese Medicine (TCM) formula developed by the Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine for the treatment of post-stroke depression (PSD). The formula is designed based on traditional principles of soothing the liver, strengthening the spleen, and relieving qi stagnation to address the psychological and physiological symptoms following a stroke. Clinical research, including trials registered in the Chinese Clinical Trial Registry (ChiCTR), has investigated its efficacy in improving Hamilton Depression Rating Scale (HAMD) scores and its regulatory effects on serum cytokine levels, which are often elevated in patients with depression. It is typically administered orally as a decoction or liquid preparation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoyao Jieyu.